Executive summary In this Commission, we argue that a combination of poor quality science,
unclear funding models, unrealistic hopes, and unscrupulous private clinics threatens …

Commercial promotion of unsupported therapeutic uses of stem cells is a global problem
that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at …

Pluripotent stem cells (PSCs) hold great potential for novel therapeutic approaches to
regenerate or replace functionally impaired tissues. Since the introduction of the induced …

A structured search reveals that online marketing of stem-cell-based interventions is skewed
toward developed economies including the United States, Ireland, Australia, and Germany …

Objective To identify the frequency and qualitative characteristics of stem cell-related
marketing claims made on websites of clinics featuring common types of complementary …

Human embryonic stem cells (hESCs) are promising in regenerative medicine. Although
several hESC-based clinical trials are under way, a widely accepted standard of clinical …

This book discusses how the global governance of the life sciences can be improved in the
face of emerging powers. The rise of India's and China's life sciences are used as examples …

In this article, we explore regulatory developments in stem cell medicine in seven
jurisdictions: Japan, China, India, Argentina, Brazil, the USA and the EU. We will show that …

During the COVID‐19 pandemic, in addition to the pandemic itself, a phenomenon called an
'infodemic'—defined by the World Health Organization as the spread of misleading …

Stem cell therapies have been demonstrated in the laboratory as an effective option in
treating a number of neurological disorders, including stroke. By targeting the subacute and …